A First in Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Intravenous (IV) Dose of GSK2831781 in Healthy Volunteers and Patients With Plaque Psoriasis

Name: A First in Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Intravenous (IV) Dose of GSK2831781 in Healthy Volunteers and Patients With Plaque Psoriasis
Published: 2014
License: Public Domain

GlaxoSmithKline · 2014

ClinicalTrials.gov · Datasets · License: Public Domain · 2014

Open Source ↗

biopsy psoriasis safety t-cells

psoriasis, tuberculin purified protein derivative, delayed type hypersensitivity, biopsy, induration, first time in human, t-cells, lag-3, safety, gsk2831781, interventional, phase1

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

A First in Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Intravenous (IV) Dose of GSK2831781 in Healthy Volunteers and Patients With Plaque Psoriasis

Related documents